Immunization

Megan Smith, PharmD, discusses how pharmacists have taken reigns in boosting pneumococcal vaccine rates across health care.

Exploring the real-time capabilities of chatbots and artificial intelligence (AI), researchers investigate how this technology would impact older adults’ pneumococcal vaccine rates.

This announcement is another move stemming from the federal government's skeptic views on vaccine technology and its efficacy among US patients.

Vaccine hesitancy rises as new recommendations emerge, highlighting pharmacists’ crucial role in addressing misinformation and improving immunization rates.

Researchers explore community-acquired pneumococcal-related hospital admissions among adults from 2000 to 2019 and assess pneumococcal immunization’s impact after the year 2015.

The agency’s findings spur promises of significant change to the development and recommendations surrounding various immunizations.

Researchers investigate serotype distribution and antimicrobial resistance among children in Mexico with pneumococcal meningitis.

The CDC states that the claim “vaccines do not cause autism” is not evidence based because studies have not ruled out the possibility that infant vaccines cause autism.

The study highlights disparities in COVID-19 vaccine access, revealing urban pharmacies excel while rural areas face significant challenges, urging policy changes for equity.

With disease cases increasing substantially between 2012 and 2024, higher-valent vaccines are necessary to protect against nonvaccine serotypes and invasive pneumococcal disease.

Study findings highlight the need for further exploration into the racial and ethnic trends of pneumococcal vaccination rates.

To optimize vaccine strategies among young people with Down syndrome, researchers explore the prevalence of adequate immune responses following pneumococcal vaccination.

A recent study reveals COVID-19 vaccine safety and varying disease activity impacts for systemic lupus erythematosus patients, highlighting important insights for immunization.

Pneumococcal conjugate vaccines significantly reduce pneumonia incidence in children, but safety concerns warrant further investigation in future studies.

Georgia Travlos, PharmD, discusses changes in influenza and respiratory syncytial virus immunizations and coadministration best practices.

PCV21 improved all outcomes for individuals aged 19 to 64 years, including invasive pneumococcal disease, postmeningitis sequelae, and nonbacteremic pneumococcal pneumonia.

Investigators explore how long COVID impacts trust in vaccines, revealing diverse patient experiences and the need for better communication in public health.

A study shows young adults with 3 or more COVID-19 vaccine doses experience fewer symptoms, emphasizing vaccination's critical role in public health.

As misinformation persists, health experts and research point to pharmacists as key communicators in building trust and boosting immunization rates.

Using the PhotoVoice methodology, researchers conduct a study exploring Latinx adolescents’ preferences and the impacts of the COVID-19 pandemic and vaccine messaging.

With uncertainty in dosing recommendations, researchers aim to assess the efficacy of pneumococcal conjugate vaccines for the pediatric population.

Amid recent measles outbreaks in Texas and Ohio, researchers aim to understand MMR vaccine coverage following postelimination outbreaks throughout the country.

Further, after the introduction of the pneumococcal conjugate vaccine 10, investigators note a decrease of infections caused by multidrug resistance infection.

The vote for state and local jurisdictions requiring a prescription for administration of COVID-19 vaccines failed after a tiebreaker vote from the committee chair.

The recommendations are provided through the West Coast Health Alliance and pull from guidance from the American Academy of Pediatrics and other organizations.